Here are three things to know:
1. The Agência Nacional de Vigilância Sanitária granted Bioventus approval to market the single-injection joint-fluid treatment for mild to moderate hip and knee osteoarthritis.
2. Pfizer has more than 100 sales representatives throughout Brazil. The company will offer Durolane as part of its arthritis pain management portfolio.
3. According to Bioventus’ CEO Tony Bihl, Brazil is the largest Latin American market for osteoarthritis pain solutions.
More articles on biologics:
Orthobiologics company completes 250 cases with OsteoCrete magnesium-based bone void filler: 3 notes
Maryland Stem Cell Research Fund awards 1st round of $8.2M funding initiative: 5 things to know
5 things to know about the global orthobiologics market
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
